Skip to main content
Clinical Trials/NCT06641830
NCT06641830
Enrolling By Invitation
Not Applicable

A Pediatric Cardiomyopathy Cohort Study: the Emerging Role of CMR in Clinical Practice

West China Second University Hospital1 site in 1 country800 target enrollmentSeptember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pediatric Cardiomyopathy
Sponsor
West China Second University Hospital
Enrollment
800
Locations
1
Primary Endpoint
Major adverse cardiovascular events
Status
Enrolling By Invitation
Last Updated
last year

Overview

Brief Summary

This observational study aims to manage children with cardiomyopathy in the long term. It collects baseline data, laboratory test data, and medical imaging data during the hospitalization and follow-up.

During their disease progress, participants will undergo cardiovascular magnetic resonance, echocardiography, electrocardiography, laboratory tests, and when hospitalization and follow-up, and the baseline data will be collected in the admission. All the above examination data will be analysed to assess the clinical characteristics, current status of diagnosis and treatment, and the prognostic risk factors for children with cardiomyopathy.

Registry
clinicaltrials.gov
Start Date
September 1, 2024
End Date
September 30, 2034
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
West China Second University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ling-Yi Wen

Principal Investigator

West China Second University Hospital

Eligibility Criteria

Inclusion Criteria

  • Pediatric patients diagnosed with cardiomyopathy.

Exclusion Criteria

  • a history of cardiovascular disease ( such as congenital heart disease, cardiomyopathy, rheumatic heart disease, valvular disease ).
  • Mentally abnormal.
  • Poor compliance.
  • Heart, kidney and other important organs were seriously incomplete.

Outcomes

Primary Outcomes

Major adverse cardiovascular events

Time Frame: 10 years after the onset

Major adverse cardiovascular events including cardiac death, transient ischemic attack or stroke, myocardial infarction, arrhythmia, heart failure, severe valvular disease, percutaneous coronary intervention, coronary artery bypass graft, and other cardiovascular surgery.

Study Sites (1)

Loading locations...

Similar Trials